Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu AF28996
- Development stage
- Phase 2
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lu AF28996 is an orally administered small molecule drug under development by Lundbeck for the treatment of Parkinson's disease. It acts as a potent, long-acting dopamine D1 receptor and dopamine D2 receptor agonist, aiming to restore dopaminergic signaling in the brain to improve motor symptoms associated with Parkinson's disease. The compound is currently in phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with Parkinson's disease[1][2][5]. Lu AF28996 is considered a new molecular entity and has not been granted orphan drug status[1].
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on Lu AF28996.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu AF28996.